



The Medical **Bulletin**

Drug Corner

SGLT2 Inhibitors in Acute Heart Failure

- EMPULSE trial has got published in Nature Medicine on 28th Feb 2022 but findings were presented at AHA meeting on November 14th 2021
- EMPLUSE trial results will impact the practice of clinicians worldwide
- If strongly opens a new window for Empagliflozin in patients with acute heart failure as 36% more likely to “experience a clinical benefit” over the next 90 days compared with patients taking a placebo.
- Now there is very vital piece of evidence for consideration of empagliflozin in Acute Heart Failure in patients hospitalized. Adding a new patient profile in which we can start empagliflozin in hospital. Starting SGLT2 inhibitors as soon as in the hospital, shown to be safe in EMPULSE.
- Empagliflozin versus placebo was also associated with fewer deaths, improvement in quality of life, and greater reduction in body weight.
- At present there is no FDA green signal to start SGLT2 Inhibitors in the setting of Acute Heart Failure.

*Dr N. K. Singh
MD, FICP. Diabetologist physician,
Dhanbad*